Atlas Trials

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Clinical trial NCT07169617 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07169617
Sponsor
National Cancer Institute (NCI)
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Lung Carcinoma
Start date
2026-07-01
Primary completion
2029-03-30
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.